ARTV vs. AUTL, ALGS, VIR, CGEM, RLAY, CRGX, IMTX, FDMT, TECX, and REPL
Should you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Autolus Therapeutics (AUTL), Aligos Therapeutics (ALGS), Vir Biotechnology (VIR), Cullinan Therapeutics (CGEM), Relay Therapeutics (RLAY), CARGO Therapeutics (CRGX), Immatics (IMTX), 4D Molecular Therapeutics (FDMT), Tectonic Therapeutic (TECX), and Replimune Group (REPL). These companies are all part of the "biological products, except diagnostic" industry.
Artiva Biotherapeutics (NASDAQ:ARTV) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk.
Artiva Biotherapeutics' return on equity of 0.00% beat Autolus Therapeutics' return on equity.
Autolus Therapeutics received 215 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 67.48% of users gave Autolus Therapeutics an outperform vote.
Artiva Biotherapeutics currently has a consensus price target of $21.25, indicating a potential upside of 112.50%. Autolus Therapeutics has a consensus price target of $8.70, indicating a potential upside of 121.37%. Given Autolus Therapeutics' higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than Artiva Biotherapeutics.
Artiva Biotherapeutics has higher revenue and earnings than Autolus Therapeutics.
In the previous week, Autolus Therapeutics had 5 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 7 mentions for Autolus Therapeutics and 2 mentions for Artiva Biotherapeutics. Autolus Therapeutics' average media sentiment score of 1.02 beat Artiva Biotherapeutics' score of 0.94 indicating that Autolus Therapeutics is being referred to more favorably in the news media.
72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Autolus Therapeutics beats Artiva Biotherapeutics on 7 of the 13 factors compared between the two stocks.
Get Artiva Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artiva Biotherapeutics Competitors List
Related Companies and Tools
Free ARTV Stock Alerts